Monthly Archives: March 2012

Mayo v. Prometheus – A European View

A Guest Post from Paul Cole, European Patent Attorney, Lucas & Co; Professor of IP law, Bournemouth University. Is a claim to an assay patent-eligible when all its features are known save for how it should be interpreted? The interpretation … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , , | 1 Comment

Legal Challenge To “ObamaCare” Threatens Generic Biologicals

What should not be lost on pharma/biotech patent attorneys or their clients, amidst all the attention given to the Supreme Court’s review of the “Patient Protection and Affordable Health Care Act” – public law 111-48, is that it contains the … Continue reading

Posted in Follow-On Biologics | Tagged , , , , | 1 Comment

Supreme Court Remands In Myriad Appeal

Today, as predicted by many commentators, the Supreme Court set aside the ruling by the Fed. Cir. that claims to isolated DNA sequences that are the BRCA 1 or 2 gene, or fragments thereof, are patentable subject matter. The Supreme … Continue reading

Posted in Federal Court | Tagged , , , , , , , , , , , , | 1 Comment

“Handbook of Quality Procedures Before the EPO”

The ECP, epi and Business Europe have collaborated to produce a downloadable, fifty page guide to practice before the EPO. While not binding on Examiners, it was issued under the authority of the EPO and is a sort of mini-MPEP, … Continue reading

Posted in EP and UK Practice | Tagged , , , , , , , , | Leave a comment